[The impact of statins use in clinically localized prostate cancer treated with radical prostatectomy].
BACKGROUND
Use of statins has been associated with reduced risk, progression and mortality of some tumors, including prostate cancer (CaP). According to recent Studies, long-term treatment with statins significantly reduces the risk of PC and also confers a protective effect against advanced or aggressive CaP. However, there is no conclusive data regarding the potential effect on patients diagnosed with clinically localized CaP undergoing radical treatment.


METHODS
A retrospective study was performed in a cohort of 250 patients that did not undergo screening and diagnosis in clinical practice of localized CaP (T1c-T2cNxM0). All patients were treated with radical prostatectomy between 2001 and 2008. Data about clinical and pathological findings, and also the existence of dyslipemia as well as treatment with statins for at least 5 years was collected and analyzed. A logistic regression analysis was performed to determine the independent predictive variables related with a more favorable pathology.


RESULTS
In our study, we found a relationship, using a univariate analysis, between treatment with statins and the presence of insignificant carcinoma in the group with low or intermediate risk of recurrence. However, this relationship is not independent when we applied a multivariate analysis.


CONCLUSIONS
Hypothesis about the potential effect of the statins preventing or inhibiting the development of high risk CaP needs to be proven applying specific clinical trials designed for this purpose. There isn't conclusive data that demonstrate that statins lower the risk of development of potentially lethal high grade CaP.
Rijo Mora
Enrique
E
Servicio de Urología, Hospital del Mar, Barcelona, España. erijo@imas.imim.es
Lorente Garin
José A
JA
Bielsa Galí
Oscar
O
Frances Comalat
Albert
A
Fumadó Ciutat
Lluis
L
Arango Toro
Octavio
O
D000368:Aged; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D012189:Retrospective Studies
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors